blastic leukemia, resulting in an accumulation of immature lymphoid progenitor cells, which is consistent with an essential role for these factors in lympohid differentiation (24, 25). In T cells, ablation of IKZF3-mediated repression of IL-2 gene expression provides a mechanism for increased IL-2 production in response to lenalidomide. The teratogenicity of thalidomide and the efficacy of lenalidomide in myelodysplastic syndrome may be mediated by alternative substrates in different cellular lineages.
Thalidomide-like drugs such as lenalidomide are clinically important treatments for multiple myeloma and show promise for other B cell malignancies. The biochemical mechanisms underlying their antitumor activity are unknown. Thalidomide was recently shown to bind to, and inhibit, the cereblon ubiquitin ligase. Cereblon loss in zebrafish causes fin defects reminiscent of the limb defects seen in children exposed to thalidomide in utero. Here we show that lenalidomide-bound cereblon acquires the ability to target for proteasomal degradation two specific B cell transcription factors, Ikaros family zinc finger proteins 1 and 3 (IKZF1 and IKZF3). Analysis of myeloma cell lines revealed that loss of IKZF1 and IKZF3 is both necessary and sufficient for lenalidomide's therapeutic effect, suggesting that the antitumor and teratogenic activities of thalidomide-like drugs are dissociable.
F ifty years ago, thalidomide was used for insomnia and morning sickness but was later banned because of its teratogenicity, manifest as profound limb defects. Thalidomide and the related drugs lenalidomide and pomalidomide (IMiDs) have regained interest, however, as immunomodulators and antineoplastics, especially for multiple myeloma and other B cell malignancies (1) (2) (3) . Nonetheless, the biochemical mechanisms underlying their teratogenic and therapeutic activities, and whether they are linked, are unknown.
In this regard, thalidomide was recently shown to bind to cereblon, which is the substraterecognition component of a cullin-dependent ubiquitin ligase, and to inhibit its autoubiquitination activity (4) . Treatment of zebrafish with cereblon morpholinos or thalidomide caused fin defects (4), suggesting that IMiDs act by stabilizing cereblon substrates. However, myeloma cells rendered IMiDs-resistant have frequently down-regulated cereblon (5) (6) (7) (8) . Conversely, high cereblon concentrations in myeloma cells are associated with increased responsiveness to IMiDs (9, 10) . Collectively, these observations suggest that IMiDs are not simply cereblon antagonists but, instead, alter the substrate specificity of cereblon to include proteins important in myeloma.
To look for such proteins, we made a plasmid library encoding 15,483 open reading frames (ORFs) fused to firefly luciferase (Fluc), knowing that the stabilities of such fusions are usually influenced by the ubiquitin ligase(s) for the corresponding unfused ORF (11) (12) (13) . Indeed, Elledge and co-workers used a green fluorescence protein (GFP)-ORF library to monitor the stabilities of thousands of ORFs after specific perturbations (13) . Partly on the basis of their work, we inserted a renilla luciferase (Rluc) reporter into each ORF-luciferase cDNA for normalization purposes and placed both reporters under internal ribosome entry site (IRES) control (Fig. 1A and  fig. S1 ).
In pilot experiments 293FT embryonic kidney cells grown in multiwell plates were transfected with the ORF-luciferase library (one ORF per well) and treated with the proteasome inhibitor MG132, the hydroxylase inhibitor dimethyloxalylglycine (DMOG), or vehicle. Fluc/Rluc values measured 36 to 48 hours later were stable over a wide range of input plasmid concentrations ( fig. S2 ). As expected, MG132 stabilized many proteasomal substrates and DMOG stabilized HIF1a, which is rapidly degraded when prolyl hydroxylated ( fig. S3 ). 
REPORTS
Next, we used this approach to identify changes in protein stability in 293FT cells treated with lenalidomide (Fig. 1A and fig. S4 ). A total of 2113 ORF-luciferase fusions produced luciferase signals that were undetectable or highly variable (>50% SD), leaving 13,370 for analysis. As expected, most ORFs were unaffected by lenalidomide (Fig. 1B, fig. S5 , and table S1). The 107 ORFs that were >3 SDs from the mean (46 ORFs plus 61 ORFs displaying decreased or increased Fluc/Rluc ratios after lenalidomide treatment, respectively) were retested in secondary assays. One down-regulated ORF (IKZF3) and one up-regulated ORF (C11orf65) retested positively (table S2) .
C11orf65 was unaffected by lenalidomide when fused to a hemagglutinin (HA) epitope tag instead of Fluc and so was not studied further ( fig. S6 ). By contrast, lenalidomide downregulated IKZF3 and its paralog IKZF1, which had fallen just outside the 3-SD cut-off in the primary screen, fused to either Fluc or HA (Fig.  1 , B and C, and table S1). These effects were specific because lenalidomide did not affect exogenous IKZF2, IKZF4, IKZF5, or the B cell transcription factor IRF4 ( Fig. 1C and fig. S7 ). Similar results were obtained with two common splice variants (V1 and V2) of IKZF1 and IKZF2 ( Fig. 1C and fig. S7 ) and with pomalidomide ( fig. S8 ). Down-regulation of exogenous IKZF1 was blocked by MG132 and by MLN4924, which inhibits cullin-dependent ubiquitin ligases ( Fig. 1D) (14, 15) .
Consistent with these findings, lenalidomide down-regulated endogenous IKZF1 in U937 leukemia cells ( fig. S9 ), which do not express IKZF3, and both IKZF1 and IKZF3 in MM1S and L363 myeloma cells (Fig. 1E ) unless the cells were pretreated with MG132 or MLN4924 ( Fig. 1E  and fig. S9 ). Multiple IKZF1 bands were detected by immunoblot analysis, presumably due to alternative splicing. Lenalidomide did not alter IKZF1 and IKZF3 mRNA levels, consistent with it acting posttranscriptionally ( fig. S10 ).
Down-regulation of cereblon in 293FT cells with a doxycycline-inducible short hairpin RNA (shRNA) prevented the destabilization of exogenous, HA-tagged, IKZF1, by lenalidomide ( Fig. 2A  and fig. S11 ). Similarly, cereblon shRNA blocked the down-regulation of endogenous IKZF1 by lenalidomide in U937 leukemia cells (U937) and myeloma cells (L363 and KMS34) (fig. S12, A to C). We also used clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing (16, 17) to generate CRBN−/− 293FT cells, which were then transfected to produce IKZF1 fused to Fluc ( Fig. 2B and fig. S13 ). This defect was rescued by wild-type cereblon, but not a lenalidomideresistant cereblon mutant (YWAA) (4) (Fig. 2B) .
Similar results were obtained with a second CRBN−/− 293FT subclone, but not in subclones with detectable amounts of cereblon ( fig. S13) . Moreover, endogenous IKZF1 and IKZF3 were not degraded by lenalidomide in two independent CRBN−/− MM1S myeloma cell lines generated with CRISPR (Fig. 2, C and D) .
Lenalidomide enhanced the binding of IZKF1 and IKZF3, but not IKZF2 and IKZF5, to the cereblon ubiquitin ligase in cotransfection experiments using MG132-treated 293FT cells ( fig. S14,  A and B) . Next, we immunoprecipitated FLAGtagged IKZF1 and IKZF2 from CRBN−/− cells that were or were not treated with lenalidomide. The immobilized immunoprecipitates were then used to capture endogenous cereblon from CRBN+/+ cells (Fig. 3A) or exogenous cereblon from CRBN−/− cells transfected to produce wild-type cereblon or the YWAA variant (Fig. 3B) . In both cases, the cells producing cereblon were or were not treated with lenalidomide before lysis. Wild-type cereblon, but not the YWAA variant, bound specifically to IKZF1 provided that it was exposed to lenalidomide, consistent with lenalidomide binding directly to cereblon rather than to IKZF1 (Fig. 3, A (Fig. 3C ) and in vitro (Fig. 3D) after exposure to lenalidomide.
We analyzed a series of IKZF1/2 chimeras and determined that the region of IKZF1 corresponding to residues 108 to 197 of IKZF1(V2) mediated lenalidomide-dependent binding to cereblon ( fig. S18 ). Within this region, there are only seven amino acid differences between IKZF1 and IKZF2 ( fig. S19, A and B) . Changing IKZF1 residue Q146 (or IKZF3 Q147) to the corresponding residue in IKZF2 (histidine) abrogated cereblon binding and lenalidomide-induced degradation (figs. S19C and S20). Conversely, the reciprocal change in IKZF2 rendered it partially sensitive to lenalidomide ( fig. S19D ).
Next, we tested six myeloma cell lines for their sensitivity to lenalidomide in vitro (Fig. 4, A and  B) . Previous studies showed that lenalidomide, at least indirectly, down-regulates IRF4 and linked this to its antimyeloma activity (5-8). MM1S, KMS34, and L363 cells were sensitive to lenalidomide in vitro whereas KMS11, RPMI8226, and OCImy5 cells were relatively resistant (Fig.  4B ). In the three sensitive lines, IKZF1 and IKZF3 were down-regulated by lenalidomide (Fig. 4A) . In two of these lines (MM1S and KMS34), loss of IKZF1 and IKZF3 was followed by a decrease in IRF4, consistent with IRF4 acting downstream of IKZF1 and/or IKZF3 in these cells (Fig. 4A and  fig. S21A ). Indeed, we confirmed decreased IRF4 mRNA and decreased binding of IKZF1 to the IRF4 locus by chromatin immunoprecipitation (ChIP) in MM1S cells treated with lenalidomide ( fig. S21) . The third sensitive cell line, L363, expressed high basal amounts of IRF4 that were unaffected by lenalidomide, providing evidence that the antiproliferative effects of this drug involves at least one target other than IRF4 (Fig.  4A and fig. S21A ).
Two of the resistant lines had relatively high basal amounts of IKZF1 (OCImy5) or IKZF3 (KMS11) and corresponding low amounts of cereblon compared to the sensitive lines, and downregulation of IKZF1 and IKZF3 by lenalidomide was attenuated in the third (RPMI8226) (Fig. 4A) . IRF4 was not down-regulated by lenalidomide in the three resistant lines.
Next, we performed competition experiments with cells in which IKZF1 or IKZF3 was suppressed with shRNAs or enhanced through expression of lenalidomide-resistant versions of IKZF1 or IKZF3. Down-regulation of either IKZF1 or IKZF3 in the lenalidomide-sensitive cell lines MM1S and KMS34 markedly decreased cellular fitness compared to cells expressing a control shRNA and was associated with down-regulation of IRF4 (Fig. 4, C and D, and fig. S22 ). Notably, down-regulation of either IKZF protein led to loss of the other. Conversely, expression of the stabilized versions of IKZF1(Q146H) or IKZF3 (Q147H) conferred lenalidomide resistance to MM1S cells (Fig. 4, E and F, and fig. S23) and  KMS34 cells (fig. S24) . Ectopic expression of a T cell-specific Ikaros family member, IKZF2, which is naturally lenalidomide resistant (Fig.  1C) , had similar effects (figs. S23G and S25). The effects of expressing IRF4 itself were much less pronounced, again suggesting that IKZF1 and IKZF3 have additional targets that are relevant for lenalidomide's antimyeloma activity (Fig. 4E  and fig. S23H ). It remains to be seen whether lenalidomide-resistance conferred by IKZF family members is due primarily to transcriptional activation of their target genes or to noncanonical functions.
Our findings link lenalidomide's antimyeloma activity to down-regulation of IKZF1 and IKZF3, two transcription factors that play critical roles in B cell development and are highly expressed in B cell malignancies, including myeloma ( fig. S26)  (18-21) . There are many other examples of cancers that become addicted to transcription factors that specify cell lineage (22, 23) . Although IKZF1 is a tumor suppressor in some other B cell malignancies (24), there is precedence for the same gene acting as either a tumor suppressor or an oncogene in different contexts.
Ikaros family members can serve as transcriptional activators or repressors in different settings. For example, IKZF1 and IKZF3 repress interleukin-2 (IL-2) expression in T cells, thus explaining how IMiDs induce IL-2 production in vivo (19, 25, 26) .
The proteasomal inhibitor bortezomib has antimyeloma activity, alone and in combination with lenalidomide, although the pertinent proteasomal substrates are debated (27, 28) . This creates a paradox because proteasomal blockade prevents the destruction of IKZF1 and IKZF3 by lenalidomide. Proteasomal blockade by bortezomib is incomplete with therapeutic dosing, however, which might allow sufficient clearance of IKZF1 and IKZF3 while retaining bortezomib's other salutary effects. It is also possible that these two proteins, once polyubiquitylated, are inactive or dominant-negatives.
Earlier work suggested that thalidomide's teratogenic effects reflected cereblon inactivation, whereas our findings indicate that the therapeutic effects of the IMiDs reflect a cereblon gain of function. Notably, cereblon might have additional substrates that were not in our fusion library, could not be recognized as luciferase fusions, or require accessory proteins or signals absent in 293FT cells. Regardless, our findings create a path to uncouple the therapeutic and teratogenic activities of the IMiDs.
It is not yet clear whether lenalidomide's effect on cereblon is hypermorphic or neomorphic. Precedence for the latter is provided by rapamycin, which converts FKBP12 into a TORC1 kinase inhibitor and cyclosporine, which converts cyclophylin into a calcineurin antagonist (29 Mining modern genomics for cancer therapies is predicated on weeding out "bystander" alterations (nonconsequential mutations) and identifying "driver" mutations responsible for tumorigenesis and/or metastasis. We used a direct in vivo RNA interference (RNAi) strategy to screen for genes that upon repression predispose mice to squamous cell carcinomas (SCCs). Seven of our top hits-including Myh9, which encodes nonmuscle myosin IIa-have not been linked to tumor development, yet tissue-specific Myh9 RNAi and Myh9 knockout trigger invasive SCC formation on tumor-susceptible backgrounds. In human and mouse keratinocytes, myosin IIa's function is manifested not only in conventional actin-related processes but also in regulating posttranscriptional p53 stabilization. Myosin IIa is diminished in human SCCs with poor survival, which suggests that in vivo RNAi technology might be useful for identifying potent but low-penetrance tumor suppressors.
S quamous cell carcinomas of the head and neck (HNSCCs) are the sixth most common human cancer worldwide, with frequent, often aggressive recurrence and poor prognosis (1) . Established genetic and epigenetic alterations include EGFR amplifications; Trp53, H-RAS, NOTCH, PI3K/Akt, and BRCA1 mutations; and transforming growth factor-b (TGF-b) pathway repression (1). Recent whole-exome sequencing efforts have revealed hundreds of additional "lowerpenetrance" HNSCC mutations with unknown functional importance (2, 3) .
To functionally test putative "driver mutations" that confer a selective advantage and contribute to tumor progression, researchers have used RNA interference (RNAi) followed by allografting of transduced cultured cancer cells. However, orthotopic transplantations necessitate immunocompromised animals and generate wound responses, which can confound physiological relevance. We have circumvented these difficulties with noninvasive, ultrasound-guided in utero lentiviral-mediated RNAi delivery, selectively transducing single-layered surface ectoderm of living mouse embryos at embryonic day (E) 9.5 (4).
We first showed that mice transduced with Brca1 short hairpin RNAs (shRNAs) that silence BRCA1 expression recapitulate the Brca1-knockout phenotype and develop spontaneous skin and oral SCCs with long latency (5) (fig. S1 ). We accelerated tumor growth by testing hairpins in epithelial-specific, TGFb-Receptor-II conditional knockout (cKO) mice (K14-Cre;TbRII floxed/floxed ), which lose TGF-b signaling in skin, oral, and anogenital epithelia and display enhanced SCC susceptibility (6, 7). On this TbRII-cKO background, Brca1 knockdown generated SCCs with increased frequency and a factor of 4 decrease in latency ( fig.  S1 ). Having validated our sensitized approach, we devised a pooled shRNA format to carry out
